Related Experiment Video
Updated: Jul 16, 2026

Using Reverse Genetics to Manipulate the NSs Gene of the Rift Valley Fever Virus MP-12 Strain to Improve Vaccine Safety and Efficacy
Published on: November 1, 2011
Risk of autoimmune disease flares after recombinant zoster vaccine: A vaccine safety analysis based on the Vaccine
Geliang Liu1,2,3, Xinxi Zhang1,3, Yajing Wang1,3
1Shanxi Key Laboratory of Big Data for Clinical Decision, Shanxi Medical University, Taiyuan, China.
Abstract:
Since its introduction in 2017, limited research has assessed the risk of flares in patients with autoimmune disease receiving the recombinant zoster vaccine (RZV). Herein, we evaluated the RZV-related flare risk using the Vaccine Adverse Event Reporting System (VAERS), exploring relevant patient characteristics. RZV vaccination records were extracted from VAERS (2017 Q1-2024 Q3), focusing on individuals diagnosed with rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), psoriasis, or systemic lupus erythematosus (SLE). RZV-related flare cases were identified using preferred terms and symptom descriptions. Disproportionality analyses, including reporting odds ratio (ROR) and three additional algorithms, were performed. Descriptive analyses assessed clinical characteristics and time to flare onset. A total of 920 patients who received RZV were identified, with a flare incidence of 8.5% (n = 78). Disproportionality analysis showed a positive flare risk signal (ROR, 3.00; P < .001). RORs for vaccine-related flares were 7.50 (SLE), 5.61 (MS), 5.03 (RA), 3.16 (psoriasis), and 2.07 (IBD). Except for the specific autoimmune disease, flare risk was not significantly associated with age, sex, or vaccine dose. Fifty-nine percent of flares occurred within 0-3 days post-vaccination. Symptom resolution was reported for 25.6% of flare cases, mostly (70%) spontaneous. Patients with autoimmune disease were at risk of RZV-related flares. Flare risk was highest risk for patients with SLE. Close monitoring within 3 days post-vaccination is advised. We provide VAERS-based evidence to support vaccine safety evaluation, guiding the clinical management of autoimmune disease.
More Related Videos
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
08:10Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector
Published on: November 28, 2018
Related Concept Videos
Vaccinations
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Pharmaceutical Poisoning: Potential Scenarios
Microorganisms in Medicine and Therapeutics
Infectious Diseases and Their Occurrence
Vaccines